150 related articles for article (PubMed ID: 18042659)
1. The demise of anti IL-5 for asthma, or not.
O'Byrne PM
Am J Respir Crit Care Med; 2007 Dec; 176(11):1059-60. PubMed ID: 18042659
[No Abstract] [Full Text] [Related]
2. Anti-interleukin-5 therapy and severe asthma.
Gleich GJ
N Engl J Med; 2009 Jun; 360(24):2577; author reply 2578. PubMed ID: 19522047
[No Abstract] [Full Text] [Related]
3. Eosinophils in asthma--closing the loop or opening the door?
Wenzel SE
N Engl J Med; 2009 Mar; 360(10):1026-8. PubMed ID: 19264692
[No Abstract] [Full Text] [Related]
4. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
5. The trials and tribulations of anti-IL-5 em leader.
Hansel TT; Sterk PJ; Holgate ST; Barnes PJ
J Allergy Clin Immunol; 2002 Mar; 109(3):575-6. PubMed ID: 11898011
[No Abstract] [Full Text] [Related]
6. Anti-interleukin-5 therapy and severe asthma.
Zarogiannis S; Gourgoulianis KI; Kostikas K
N Engl J Med; 2009 Jun; 360(24):2576; author reply 2577. PubMed ID: 19516040
[No Abstract] [Full Text] [Related]
7. Anti-interleukin-5 therapy and severe asthma.
Szczeklik A
N Engl J Med; 2009 Jun; 360(24):2576-7; author reply 2577. PubMed ID: 19522046
[No Abstract] [Full Text] [Related]
8. New aspects in the treatment of asthma: targeted therapy.
Wang ZL
Chin Med J (Engl); 2008 Apr; 121(7):640-8. PubMed ID: 18466686
[No Abstract] [Full Text] [Related]
9. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
10. Anti-IgE or Anti-IL5: That Is the Question.
Israel E; Panettieri RA
J Allergy Clin Immunol Pract; 2018; 6(3):782-784. PubMed ID: 29150253
[No Abstract] [Full Text] [Related]
11. Combating the eosinophil with anti-interleukin-5 therapy.
Wechsler ME
N Engl J Med; 2008 Mar; 358(12):1293-4. PubMed ID: 18344569
[No Abstract] [Full Text] [Related]
12. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
14. Reassessing the Th2 cytokine basis of asthma.
O'Byrne PM; Inman MD; Adelroth E
Trends Pharmacol Sci; 2004 May; 25(5):244-8. PubMed ID: 15120489
[TBL] [Abstract][Full Text] [Related]
15. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
17. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
18. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: mepolizumab, GlaxoSmithKline.
Gnanakumaran G; Babu KS
Curr Opin Mol Ther; 2003 Jun; 5(3):321-5. PubMed ID: 12870444
[TBL] [Abstract][Full Text] [Related]
20. An update on biologic-based therapy in asthma.
Walsh GM
Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
